Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs

What Was Tested

Researchers studied Insulin Glargine in this randomized controlled trial publication.

Who Took Part

The study group was 2 patients.

PubMed indexes the participants as middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, multicenter and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Insulin Glargine and who got the comparison, which limits bias.

Running at several centres spread the Insulin Glargine study over different clinics and patient groups.

Groups ran in parallel: each of the patients stayed in one arm throughout.

Continuous glucose monitoring was carried out over two 72-h periods, at the beginning and the end of the study, and the data were used to calculate the 24-h mean blood glucose, mean amplitude of glycaemic excursions, standard deviation of blood glucose, and the mean of daily differences.

What Was Measured

The subject headings attached to it are Blood Glucose, Blood Glucose Self-Monitoring, China, Diabetes Mellitus, Type 2, Gliclazide, Glycated Hemoglobin and Hypoglycemic Agents.

Author keywords: continuous glucose monitoring, gliclazide MR, premixed insulin and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, multicenter and parallel-group study of Insulin Glargine in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (Diabetes/metabolism research and reviews), a journal based in England.

More context: the Insulin Glargine compound page.